Read twice and referred to the Committee on Finance.
The Affordable Inhalers and Nebulizers Act of 2025 requires group health plans, individual and group market issuers, ERISA plans, Medicare Parts B and D, and certain other Federal program rules to cover "specified inhaler products" (inhalation aerosols, metered dose inhalers, dry powder inhalers, inhalation solutions, bronchodilators, corticosteroids, and related administration equipment) with no deductible and with patient cost-sharing capped at $15 per 30-day supply, effective for plan years beginning on or after January 1, 2026. The bill amends the Public Health Service Act, the Internal Revenue Code, ERISA, and Social Security Act Medicare provisions to implement those requirements, creates an HHS payment program (subject to appropriations) to reimburse program-registered providers who furnish specified inhaler products to uninsured individuals and caps uninsured patients’ liability at $15 per month when payment is made, and clarifies safe-harbor treatment for high-deductible and catastrophic plans.
Scope and intrusiveness of federal mandates: liberals accept mandates to expand access; conservatives see harmful federal overreach.
Relative to its intended legislative type, this bill is a substantive policy change that is explicit about its core requirements (no deductibles and maximum $15 cost-sharing per 30-day supply for specified inhaler products) and amends the principal federal statutory frameworks to effect that change, while leaving notable administrative, fiscal, and enforcement details to implementing agencies or appropriations.
The Affordable Inhalers and Nebulizers Act of 2025 requires group health plans, individual and group market issuers, ERISA plans, Medicare Parts B and D, and certain other Federal program rules to cover "specified inhaler products" (inhalation aerosols, metered dose inhalers, dry powder inhalers, inhalation solutions, bronchodilators, corticosteroids, and related administration equipment) with no deductible and with patient cost-sharing capped at $15 per 30-day supply, effective for plan years beginning on or after January 1, 2026.
The bill amends the Public Health Service Act, the Internal Revenue Code, ERISA, and Social Security Act Medicare provisions to implement those requirements, creates an HHS payment program (subject to appropriations) to reimburse program-registered providers who furnish specified inhaler products to uninsured individuals and caps uninsured patients’ liability at $15 per month when payment is made, and clarifies safe-harbor treatment for high-deductible and catastrophic plans.
Several conforming and clerical amendments are included; HHS may implement the changes by program instruction or guidance.
On content alone, the bill addresses a clear patient affordability issue in a narrowly defined clinical area, which improves its prospects. However, it imposes cross‑statute mandates, affects Medicare/Part D financing, lacks specified offsets or appropriation amounts for the uninsured program, and will attract attention from insurers and drug makers; those factors raise legislative friction and reduce the chance of enactment without amendment, compromise, or a cost offset.
Relative to its intended legislative type, this bill is a substantive policy change that is explicit about its core requirements (no deductibles and maximum $15 cost-sharing per 30-day supply for specified inhaler products) and amends the principal federal statutory frameworks to effect that change, while leaving notable administrative, fiscal, and enforcement details to implementing agencies or appropriations.
Scope and intrusiveness of federal mandates: liberals accept mandates to expand access; conservatives see harmful federal overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and intrusiveness of federal mandates: liberals accept mandates to expand access; conservatives see harmful federal overreach.
This persona is likely strongly supportive.
The bill directly reduces out-of-pocket costs for people with asthma and COPD by capping monthly patient cost-sharing at $15 and removing deductibles for inhaler products, which aligns with goals to expand access and reduce health inequities.
They will appreciate inclusion of devices (nebulizers, spacers) and the uninsured payment program as steps toward covering vulnerable populations.
This persona is generally favorable to a targeted policy that reduces out-of-pocket costs for necessary maintenance and rescue inhalers, seeing it as a narrow, health-focused intervention.
They will appreciate the bill’s clear scope and phased effective date (Jan 1, 2026) but want information on fiscal effects, insurer premium impacts, and any administrative burdens for employers and plan sponsors.
They also favor safeguards to prevent unintended consequences (e.g., premium increases, distortion of HDHP markets) and will look for CBO scoring and implementation detail.
This persona is likely skeptical or opposed.
They view the bill as a federal mandate that restricts private plan design and expands federal intervention into employer-sponsored and exchange coverage, potentially increasing costs for employers, insurers, and taxpayers.
They will also be wary of new discretionary spending and the Secretary’s wide latitude under the uninsured reimbursement program.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill addresses a clear patient affordability issue in a narrowly defined clinical area, which improves its prospects. However, it imposes cross‑statute mandates, affects Medicare/Part D financing, lacks specified offsets or appropriation amounts for the uninsured program, and will attract attention from insurers and drug makers; those factors raise legislative friction and reduce the chance of enactment without amendment, compromise, or a cost offset.
The bill has not accumulated any surfaced votes yet.
Scope and intrusiveness of federal mandates: liberals accept mandates to expand access; conservatives see harmful federal overreach.
On content alone, the bill addresses a clear patient affordability issue in a narrowly defined clinical area, which improves its prospects.…
Relative to its intended legislative type, this bill is a substantive policy change that is explicit about its core requirements (no deductibles and maximum $15 cost-sharing per 30-day supply for specified inhaler produ…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.